Table 2.
Multivariable logistic regression analysis of confirmed virologic failure through Week 48.
| N | Parameter | Full model OR (95% CI), Pa | Backwards elimination model OR (95% CI), Pa |
| 1039 | RPV RAM(s) at baseline | 30.23 (6.25–>99), <0.001 | 40.36 (8.81–>99), <0.001 |
| Log2 of post hoc Week 8 RPV trough concentration | 3.85 (1.15–14.29)b, 0.029 | 5.00 (1.79–16.67)b, 0.002 | |
| Baseline HIV-1 subtype A6/A1 | 2.37 (0.34–22.14), 0.394 | 5.92 (1.62–22.89), 0.008 | |
| BMI (kg/m2) at baseline | 1.08 (0.96–1.22), 0.192 | 1.13 (1.02–1.24), 0.020 | |
| Prespecified INSTI polymorphism (excluding L74I [excluding mixtures with L74M]) at baseline | 0.16 (0.01–1.05), 0.057 | 0.14 (0.01–0.91), 0.038 | |
| NNRTI RAM(s) (excluding RPV RAMs) at baseline | 2.64 (0.72–9.21), 0.137 | 2.78 (0.78–9.63), 0.111 | |
| Q8W regimen | 2.76 (0.65–11.68), 0.164 | 2.77 (0.67–11.38), 0.156 | |
| L74I (excluding mixtures with L74M) INSTI polymorphism at baseline | 2.51 (0.33–13.85), 0.347 | Eliminated from model | |
| Female (sex at birth) | 1.09 (0.26–4.36), 0.899 | Eliminated from model | |
| Log2 of post hoc Week 8 CAB trough concentration | 0.66 (0.25–1.74), 0.395 | Eliminated from model |
CAB, cabotegravir; CI, confidence interval; INSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; OR, odds ratio; Q8W, every 8 weeks; RAM, resistance-associated mutation; RPV, rilpivirine.
a
95% penalized profile confidence intervals and penalized likelihood ratio P values are provided. Backwards elimination used a significance threshold of alpha = 0.2. CAB and RPV pharmacokinetic parameters were log2-transformed; therefore, the corresponding odds ratios are per halving of each variable.
b
Results are reciprocal of these so that all ORs are in same direction.